news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Data is a treasure

Data treasure

Less worries about stock trading

This week (August 19th - August 23rd), there will be three new stocks available for subscription in the A-share market, namely Jialiqi on the ChiNext, Chengdian Optics on the Beijing Stock Exchange, and Yinosi on the Science and Technology Innovation Board.

It is worth noting that Chengdian Optics is the “third stock on 920” of the Beijing Stock Exchange after Wanda Bearing and Taihu Yuanda.

According to information, Jialiqi is an important domestic supplier of aviation composite parts; Chengdian Optoelectronics mainly deals in network bus products and special display products, and the company's products are currently mainly used in the defense and military fields; Yinosi is a CRO company specializing in providing non-clinical research services in biomedicine. Sinopharm Group holds 44.23% of the company's shares and is the company's actual controller.

Specifically, the issue price of Jialiqi is 18.09 yuan per share, the upper limit for subscription from a single account is 5,500 shares, and the maximum subscription requires a market value of 55,000 yuan in the Shenzhen Stock Exchange; the issue price of Chengdian Optics is 10 yuan per share, and the upper limit for subscription from a single account is 437,000 shares; the upper limit for subscription from a single account is 8,000 shares, and the maximum subscription requires a market value of 80,000 yuan in the Shanghai Stock Exchange.

The prospectus shows that Jialiqi focuses on the research and development, production, sales and related services of aviation composite parts, and has been deeply involved in the field of military aviation for a long time. Since its establishment, the company has undertaken the research and development, design and manufacturing of many types of aviation composite parts, and its products are widely used in key equipment such as fighter jets, transport aircraft, drones, trainer aircraft, target aircraft, missiles, etc. The company's main business is located in the downstream of the composite material industry chain, and prepregs are produced and processed into aviation composite parts through autoclave molding process or hot press molding process. The company's customers cover many aircraft mainframes and scientific research institutes under the aviation industry, military scientific research and production units, and other well-known domestic aviation composite parts manufacturers.

Since 2018, the company has entered a period of rapid development. The product structure has expanded from single structural parts to integrated components with diversified sizes and structures. The application equipment has expanded from drones to fighter jets, transport aircraft, target aircraft, missiles and other key equipment models. The customer base has expanded from aircraft manufacturers to many scientific research institutes under the aviation industry, military scientific research and production units, and other well-known domestic aviation composite parts manufacturers. The company's business scale continues to grow rapidly. In the future, the company will continue to adhere to R&D-oriented, continue to expand product applications, and improve the layout of the industrial chain.

In 2021-2023, the company achieved operating income of RMB 428 million, RMB 592 million and RMB 463 million respectively, and the net profit attributable to the parent company's owners was RMB 129 million, RMB 150 million and RMB 103 million respectively.

The funds raised by the company will be used for the construction of advanced composite materials digital production base projects, R&D technology center construction projects, advanced composite materials digital manufacturing system construction projects, and to supplement working capital.

Chengdian Optoelectronics' main business is the research and development, production and sales of network bus products and special display products. Its products are currently mainly used in the defense and military fields. The company is a research and development-driven manufacturing enterprise with a number of independent intellectual property rights in the fields related to its main business, and has outstanding innovation and technological advantages. The company's main customers are subsidiaries of large domestic state-owned enterprises such as AVIC, China Shipbuilding, and China Electronics Technology Group Corporation.

Since its establishment, the company has been committed to the research and development of network bus products, especially FC network bus products. The FC network bus has the advantages of high bandwidth, low latency, high reliability, and support for multiple upper-layer protocols. It was first used in the fourth-generation fighters such as F-22 and F-35 in the world. It is currently a more advanced generation of network bus types. Under the research and development of the company's technical R&D team, many research and development results of the company's FC network bus have been identified by authoritative departments as reaching the domestic leading level, filling the gap in related fields in China. The two major series of products developed and produced by the company, high-speed network communication components and avionics network simulation, monitoring, and testing equipment, have been successively applied to the principle verification, R&D debugging, production equipment, and maintenance and inspection of major weapons and equipment in my country.

Since 2017, the company has begun to focus on the field of special displays. With the iterative optimization of the company's products and the expansion of application scenarios, customer demand has been released one after another, and the revenue share of the company's special display products has continued to increase, and it is currently one of the main revenue components. The company pioneered the application of LED display technology in the field of military simulation training. The product has undergone 5 iterations, from the initial 2m×2m ball lobe curtain rough sample to the 1m×2m ball belt curtain medium sample, and then from the 7m diameter whole ball test batch to the 5m diameter whole ball final sample. It has overcome technical difficulties such as high-density LED complex curved surface display, spherical LED display drive and control, low-latency video transmission and multi-channel video synchronization suitable for flight simulation, high-density flexible LED light panels and high-precision spherical splicing, and nonlinear distortion geometric correction for LED spherical images. Finally, in 2021, it successfully developed an LED ball screen vision system that can be used in military flight simulation training equipment, which has passed military product identification and mass supply, filling the gap in visual LED ball screen display technology in the field of domestic flight simulation systems.

In 2021-2023, the company achieved operating income of RMB 121 million, RMB 169 million and RMB 216 million respectively, and the net profit attributable to the parent company's owners was RMB 21 million, RMB 34 million and RMB 45 million respectively.

The company will invest the funds raised this time in FC network bus and LED dome screen industrialization projects, headquarters building and R&D center projects, and to supplement working capital.

Inos is a comprehensive research and development service (CRO) company that specializes in providing non-clinical research services for biopharmaceuticals. As one of the earliest companies in China to have both NMPA GLP certification, OECD GLP certification, and GLP inspection by the U.S. FDA, it is aligned with international standards and has competitive international service capabilities in the industry, providing global pharmaceutical companies and research institutions with a full range of new drug research services that meet domestic and international application standards. The company's services mainly cover three major areas: early biopharmaceutical drugability evaluation, non-clinical research, and clinical testing and translational research. The non-clinical research area specifically includes non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamics research.

In 2021-2023, the company achieved operating income of RMB 582 million, RMB 863 million and RMB 1.038 billion, respectively, and the net profit attributable to the parent company's owners was RMB 87 million, RMB 135 million and RMB 194 million, respectively.

The funds raised by the company will be used for the Inos headquarters and innovation transformation center projects, the expansion project of the high-quality non-clinical innovative drug comprehensive evaluation platform and to supplement working capital.

Source: Securities Times official microblog

Statement: All information content of Databao does not constitute investment advice. The stock market is risky and investment should be cautious.

Editor: He Yu

Proofreading: Zhu Tianting

Data treasure